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Abstract 71 
Background: Little is known about the burden of AD encountered in U.S. primary care practices 72 
and the frequency and type of skin care practices routinely used in children.  73 
Objectives: To estimate the prevalence of AD and allergic comorbidities in children 0-5 years 74 
attending primary care practices in the U.S. and to describe routine skin care practices used in 75 
this population. 76 
Design: A cross-sectional survey study of a convenience sample of children under the age of 5 77 
attending primary care practices for any reason. 78 
Setting: Ten primary care practices in five U.S. states  79 
Results: Amongst 652 children attending primary care practices, the estimated prevalence of 80 
ever having AD was 24 % (95% CI= 21-28) ranging from 15% among those under the age of 81 
one to 38% among those aged 4- 5 years. The prevalence of comorbid asthma was higher among 82 
AD participants compared to those with no AD, 12% and 4%, respectively 83 
(p<0.001).  Moisturizers with high water:oil ratios were most commonly used (i.e., lotions) in 84 
the non-AD population, whereas moisturizers with low water:oil content (i.e. ointments) were 85 
most common when AD was present. 86 
Conclusions:  Our study found a large burden of AD in the primary care practice setting in the 87 
U.S.  The majority of households reported skin care practices in children without AD that may be 88 
detrimental to the skin barrier such as frequent bathing and the routine use of moisturizers with 89 
high water: oil ratios. Clinical trials are needed to identify which skin care practices are optimal 90 
for reducing the significant risk of AD in the community. 91 
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Introduction 93 
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that usually starts in 94 
early childhood but can develop at any age.1-3 AD represents a substantial disability burden on a 95 
global scale.4  Large international studies reveal a wide range of prevalence rates in 96 
industrialized countries ranging between 10-30%, with rates varying greatly by geographic 97 
area.5-7 U.S.-specific studies find similar high rates of disease prevalence and similar geographic 98 
variability in prevalence.8,9 Most of our understanding of AD prevalence in the U.S. stems from a 99 
limited number of national population-based surveys which are now over ten years old.2,8,9 While 100 
they provide a reasonable estimate of population prevalence, population-based studies do not 101 
always accurately reflect the burden of a disease encountered in community healthcare settings - 102 
an important consideration for resource allocation by decision makers.10,11  A better 103 
understanding of the burden of AD and the associated allergic comorbidities encountered in 104 
primary care practices helps to plan disease prevention strategies appropriate to this setting.  105 
Prevention strategies that prevent AD development may also reduce allergic comorbidities that 106 
often follow AD development such as allergic asthma. 107 
 108 
Epidemiological studies identify several risk factors for AD development including climatic 109 
factors,12 cat ownership, 13proximity to traffic,14 early allergen sensitization, family history of 110 
atopic diseases, and a FLG gene mutation (a gene important for proper skin barrier function).15 111 
In a large unselected cohort from the U.K., skin barrier dysfunction as measured by 112 
transepidermal water loss at 2 days and 2 months of age was the strongest risk factor for AD 113 
development at 12 months of age- more so than a FLG mutation or family history of atopy.15   114 
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 115 
Because of the role early skin barrier dysfunction may play in AD development, our group and 116 
others have been interested in how skin care practices and moisturizer use may modify AD 117 
disease risk. Currently, there are no data to support the need for routine emollient use in healthy 118 
newborns.16 However, three  pilot trials suggest daily moisturizer therapy in high-risk 119 
populations may reduce the risk of developing AD by as much as 50%.17-19 The optimal type of 120 
moisturizer that protects against AD in not clear, although moisturizers with higher oil content 121 
are thought to enhance skin barrier function more so than lower oil content moisturizers.20  122 
Because plain water and fragrances can be an irritant to skin, fragranced moisturizers with high 123 
water content may, in theory, be detrimental to skin barrier function.  Some authors postulate that 124 
the increased use of fragranced lotions early in life may explain the rising epidemic of AD 125 
although no studies have shown this association in a rigorous manner.21 126 
 127 
In order to develop and study novel skin care interventions as a prevention strategy for AD, data 128 
are needed regarding the routine skin practices currently used by U.S. families. In preparation for 129 
a large community-based trial evaluating moisturizers for the prevention of AD, we sought to 130 
determine the prevalence of AD in children attending primary care settings using a convenience 131 
sample of children under the age of five and aimed to describe current skin care practices utilized 132 
by parents on their children both with and without AD. 133 
Methods 134 
Study Design, Population and Setting 135 
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This study, named the Community-based Assessment of Skin Care, Allergies and Eczema 136 
(CASCADE) study, was a cross sectional survey study conducted in five U.S. states. CASCADE 137 
was a planning study to determine the feasibility of conducting a large, five-year, community-138 
based pragmatic randomized controlled clinical trial to test the hypothesis that certain skin care 139 
practices can prevent or delay AD and allergic comorbidities. Study participants were dyads of 140 
parents or guardian and children 0-5 years old attending one of ten community-based pediatric 141 
(n=6) and family medicine (n=4) clinics located in Oregon, Wisconsin, Colorado, North 142 
Carolina, and Iowa. These clinics were all members of a practice-based research network 143 
(PBRN) within their respective state and were a mix of rural and suburban practices. All 144 
participating PBRNs collaborate via the Meta-network Learning and Research Center (Meta-145 
LARC) consortium, an administrative structure funded by the Agency for Healthcare Research 146 
and Quality encompassing almost 1000 primary care practices and 7000 clinicians 147 
(https://www.ohsu.edu/xd/outreach/oregon-rural-practice-based-research-network/meta-148 
larc/index.cfm, accessed April, 2018).  PBRNs serve as essential partners in translating academic 149 
research advances into real-world health improvements in the general ambulatory care 150 
population.22 The study was approved by the institutional review board (IRB#11116) of Oregon 151 
Health and Science University and recruited participants from April 2015 through January 2016.  152 
 153 
Inclusion required being a parent or legal guardian, aged ≥18 years, of a child between the ages 154 
of 0 and 5 years who was a current patient at the participating clinic; respondents also needed to 155 
be able to read and write in either English or Spanish. Potential respondents were excluded if 156 
unable to complete the questionnaire due to mental or cognitive capacity, if they or another of 157 
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the child's parents had already completed the questionnaire (ascertained by self-report), or if the 158 
child had been born preterm at less than 25 weeks of pregnancy. 159 
 160 
Recruitment  161 
The Iowa PBRN recruited participants by mail only whereas all other PRBNs used a 162 
combination of the following methods to capture as wide a sample as possible: in clinic while 163 
waiting for their appointments, mailed surveys, and electronic surveys via Research Electronic 164 
Data Capture (REDCap) hosted by OHSU. This flexibility in recruitment methods allowed for a 165 
minimal impact on clinic workflow that is critical to performing research in this setting.  Clinic 166 
staff were instructed to broadly distribute the surveys to all eligible patients attending the clinic 167 
during the enrollment period, without selecting for any demographic or medical history in order 168 
to minimize selection bias. Due to the nature of the survey distribution in a busy practice setting, 169 
refusals were not recorded, thus we are unable to report a participation rate. 170 
Instrument 171 
The questionnaire was completed by the child’s caregiver and included questions about AD 172 
history, symptoms, age of onset, presence of other atopic disorders, medications use, and skin 173 
care and bathing practices (Supplemental Figure 1.) The questionnaire was adapted from 174 
previous childhood AD surveys that have been used and validated in a community setting to 175 
measure the prevalence of AD. 2,9,23  176 
 177 
AD and severity assessment 178 
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A history of AD was determined by a positive response to the question “Have you ever been told 179 
by a health care provider that your child has eczema or atopic dermatitis?” A similar question has 180 
been shown to have adequate sensitivity and specificity to estimate the prevalence of AD in the 181 
US. 24-26  We assessed the effect of AD on the child’s sleep by asking how many nights in the 182 
past week the child's sleep had been disturbed because of a red rash or eczema. AD severity was 183 
assessed by asking respondents to rate the rash or eczema as mild, moderate, or severe. This 184 
question has been used previously in epidemiological studies to assess severity and found to be a 185 
good indicator of childhood AD burden. 2,9,27   186 
 187 
Comorbidities and Family History 188 
A history of asthma and wheezing were measured using the questions “Has your child ever been 189 
diagnosed with asthma by a healthcare provider?” and “Has your child ever had wheezing?” 190 
Food allergies were measured by asking “Has your child ever been diagnosed with a food allergy 191 
by a healthcare provider?” Family history of any atopic condition was assessed by asking the 192 
question “Has at least one of your child’s parents or older brothers or sisters (related by blood) 193 
ever had any of the following conditions: eczema, asthma, or hay fever/spring-time allergies”. 194 
Parental history of asthma was considered positive if at least one of the parents had asthma. The 195 
questions were adapted from previously validated questions used in epidemiological studies 196 
which measured comorbidities.28,29 197 
 198 
Skin Care and Bathing 199 
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Moisturizer use was assessed by answering the question “do you use a moisturizer/lotion/ oil on 200 
your child’s skin.” An affirmative response to the above question was followed by secondary 201 
questions about the type of moisturizer and the application site-all over the body or just on dry 202 
areas. Moisturizer type was assessed by asking the following question: “Which moisturizer(s) did 203 
you use on your child”. The answer choices included the most commonly used commercial 204 
moisturizers brands.; CeraVe cream, Cetaphil cream, Vaseline/ petroleum jelly, Sunflower seed 205 
oil, Aveeno, Aquaphor, Vanicream and  Johnson’s baby lotion. If the moisturizer that had been 206 
used was not listed in the answer choices that were given, the parents were instructed to check 207 
“other” and write what they were using. For a better understanding of current trends in 208 
moisturizer use, more than one answer was acceptable for this question.  We stratified 209 
moisturizers based on their content: lotion, cream, ointment or liquid oil. If the parents did not 210 
specify the type (i.e. lotion, ointment, cream or liquid oil), and the brand product could represent 211 
more than one type of moisturizer, the answer was excluded from analysis.    212 
 213 
Moisturizer frequency and bathing or shower frequency was measured using the following 214 
questions: “Over the past 3 months, on average how many days per week was a moisturizer/ 215 
lotion/oil applied to your child’s skin” and “Over the past 3 months, on average how many days 216 
per week did your child receive either a bath or shower?”  Moisturizer frequency was asked only 217 
in those participants who were using moisturizers, while bathing frequency was asked of the 218 
whole sample. We categorized frequency of moisturizer use and bathing into two categories: < 4 219 
and 4 days or more per week. Since the biological effect of most moisturizers lasts more than 220 
twenty-four hours, we considered 4 days a week or more to be frequent use.  221 
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 222 
Sample Size and Statistical Analysis 223 
A sample size of approximately 250 was estimated to provide a reasonably precise sample of 224 
disease prevalence from age 0-5 years with a 95% confidence interval within 5 percentage 225 
points. Our actual sample was significantly larger in order to obtain an adequate sample from all 226 
age groups and study sites. We excluded 9 respondents who failed to provide the child's age 227 
(n=5) and history of provider diagnosis of AD (n=3), or both (n=1); our final dataset included 228 
652 children. 229 
 230 
We calculated simple descriptive statistics overall and for AD and non-AD groups and tested 231 
differences with Chi square (χ2) tests. To estimate age-specific characteristics of AD, we used 232 
predictive margins from a logistic regression model with clustered standard errors to account for 233 
correlation between respondents from the same clinic. Similarly, estimates of comorbid 234 
conditions and skin care practices resulted from logistic or log-binomial (relative risk) models 235 
with clustered standard errors and including age, in months, as a covariate to adjust for this 236 
effect. All analyses were performed using Stata SE for windows version 14 (Stata Corp, College 237 
Station, Texas). 238 
 239 
Results 240 
A total of 652 caregivers with children aged between 0-5 years participated in the study with 24 241 
% (95% CI 21-28) overall parent-reported prevalence of AD. The mean ± standard deviation of 242 
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age of participants was 22.5 ±19.4 months, and the mean age at which AD first appeared was 243 
9±10.4 months. Those with AD were far more likely to experience dry skin than those in the 244 
non-AD group (63% vs 17%, p <0.001).There were no significant differences between those 245 
with AD compared to the non-AD group in regards to sex, parent language, race/ethnicity, or 246 
geographic distribution. Participants' characteristics are summarized in Table 1.  247 
.   248 
AD prevalence and severity   249 
As expected, AD prevalence steadily increased with age, ranging from 14.5 % among children 250 
less than 1 year old to 38 % among children 4-5 years old (p<0.001). Overall, 58% of children 251 
with AD had mild symptoms, 39% had moderate and only 3% (4 children) had severe disease. 252 
Among the same children with AD, 21 % had reported AD-related sleep disturbance in the 253 
previous week. Although we did not detect trends in severity or AD- related sleep disturbance by 254 
age, prescriptions for eczema medications were common overall (75% of children with AD) and 255 
increased with age. 67% and 69 % of children less than 1 year of age and 1-2 years-olds, 256 
respectively were prescribed medication compared to higher percents, 75% and 86%, for older 257 
age groups (2-3 years, and 4-5 years, respectively; p = 0.019), see Table 2. 258 
 259 
Comorbidities and Family History 260 
Children with AD in this study had a higher reported prevalence of certain comorbidities with 261 
known or suspected links to AD. Age adjusted prevalence of asthma was about three times as 262 
high in the AD group compared to non-AD group (prevalence ratio (PR) 3.0, p<0.001). History 263 
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of wheezing, including wheezing without a cold, were higher among the AD population 264 
compared to the non-AD group (PR 1.4 and 1.8, p< 0.05). Food allergies were 3.7 times more 265 
common among those with AD (p=0.005). Family history of any atopic condition—a known risk 266 
factor for AD—was also significantly higher in the AD group (PR 1.3, p< 0.001). (Table 3) 267 
 268 
 269 
Skin Care and Bathing 270 
Use of moisturizer (at any frequency) was common in the whole sample; however it was found 271 
to be significantly higher among the AD group (90%) compared to the non-AD group (74%, p 272 
<0.001).  For children without AD, parents most commonly used lotions (64%) on their children, 273 
whereas parents of children with established AD most commonly used oil-rich moisturizers such 274 
as cream or ointment (65%) possibly in response to guideline-driven recommendations for AD 275 
treatment by their health practitioners. The mean number of days used per week for the overall 276 
sample was 4.3 and the mean number of daily bath/showers per week was 4.6. Among those who 277 
used moisturizer, the majority (65%) applied it 4 or more days per week and there was no 278 
significant difference in moisturizer frequency application when stratified by age. Those with 279 
AD applied moisturizers more days per week than those in the non-AD group (4 or more days a 280 
week = 75% vs. 60%, P =0.001). Overall 41% of the children received a bath/shower less than 4 281 
days/week, while 59% received a bath/shower 4 or more days per week. There was no significant 282 
difference in bathing frequency between those with AD compared to those without AD. When 283 
bathing frequency was examined by age, those who were under the age of one received less bath/ 284 
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shower per week compared with the older participants regardless of AD status, P < 0.001. 285 
Summaries of skin care practices appear in Tables 4 and 5. 286 
Discussion  287 
We estimated the prevalence of AD among children age 0-5 attending community based primary 288 
care practices to be approximately 24%, with a mean age of AD onset in the first year of life. 289 
Parent reported AD severity was mild in more than half of participating children, and 20% of 290 
those with AD, had their sleep disturbed at least once a week as a result of their AD. As 291 
anticipated, a higher prevalence of AD-associated comorbidities and a family history of atopic 292 
conditions were found among those with AD. The majority of parents were using some kind of 293 
moisturizer on their child’s skin on a regular basis; children with AD were more likely to receive 294 
creamy and oily moisturizers while children without AD were receiving lotions primarily. This 295 
large community based study is the first study to describe the pediatric AD burden within 296 
community-based primary care practices and provides important insight into skin care practices 297 
that may be modifiable in future disease prevention studies.  298 
 299 
A higher prevalence of AD (24%) was found in children under the age of five in our study 300 
compared to U.S. population-based studies using data from the National Survey of Children 301 
Health (NSCH). Shaw found prevalence rates ranging between 13.12 % - 14.73% among those 302 
under the age of four.8 Similar to our findings, previous studies of chronic illnesses found a 303 
higher prevalence rate in the primary care setting compared to the population setting.10,11 304 
Measuring the prevalence of AD in children attending primary care clinics reflects the  disease 305 
burden in these community clinics, while population-based studies provide estimates for a  306 
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general population that may or may not be accessing the healthcare system.10 Understanding the 307 
disease burden is important from both perspectives to provide information to investigators, 308 
clinicians, patients and resource allocation stakeholders.  309 
  310 
Similar to population-based studies, our study confirmed that allergic comorbidities are also 311 
common in children with AD attending community-based primary care clinics.  The consistency 312 
of our data with other national surveys of allergic diseases lends support that our sample 313 
population adequately represents the U.S. AD population. For example, the overall prevalence of 314 
asthma found in our sample population of 0-5 year olds of 7% closely mirrors the Centers for 315 
Disease Control and Prevention (CDC) statistics from the Behavioral Risk Factor Surveillance 316 
System (BRFSS) 2013 data which measured the life time prevalence of asthma in the general 317 
U.S. population to be 7.3% among children under the age of five.30  We also confirmed the 318 
higher rate of asthma among those with AD (16%) compared to non-AD children (4%) 319 
consistent with many previous studies.31-33 Patients with AD also had a higher prevalence of a 320 
family history of allergic disease in our study confirming that a family history of atopy 321 
represents an important risk factor for AD development. 322 
 323 
This study provides insight into skin care practices used in the very young- a subject of relatively 324 
limited study especially given our new understanding of the importance of the skin barrier in the 325 
development of AD. Kelleher and colleagues found skin barrier function in the first 2 months of 326 
life to be the strongest predictors of AD development.34 Thus, skin care practices that have the 327 
potential to alter skin barrier function may represent important determinants or modifiers of AD 328 
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development. In this present study, the majority of caregivers applied some kind of moisturizer 329 
on their child’s skin, even among children without reported AD diagnosed by a healthcare 330 
provider. As expected, children with AD reported more frequent use of thick moisturizers (i.e. 331 
creams and ointments) than those without AD, as this is the most common first-line treatment for 332 
mild AD. Thus, children with AD appear to receive appropriate education regarding moisturizer 333 
use supported by published treatment guidelines.35 In those without AD, we found the majority 334 
of parents used more water-based moisturizers (i.e. lotions) on the skin, as opposed to thicker 335 
moisturizers, with the majority of usage more than 4 days per week.  These skin care practices 336 
are similar to those described in a single-center study in Oregon and confirm findings from a 337 
market-based study showing a very high use of water-based moisturizers (lotions) in babies on a 338 
regular basis.36,37 This high use of moisturizers are likely a result of cultural preferences or 339 
marketing as skin care guidelines for neonates do not recommend routine use of mositurizers.  340 
The U.S. Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN) released 341 
updated guidelines for neonate and infant skin care that state it is unclear whether the routine use 342 
of moisturizers benefits infant health.16 Certain moisturizers could potentially even harm the skin 343 
barrier with frequent use such as those with irritants, fragrances or high water content,38-41 thus 344 
potentially provoking AD in genetically-susceptible neonates. There is no clinical evidence, 345 
however, that the use of fragranced lotions in neonates promotes AD.  The guidelines do 346 
recommend moisturizer use for dry or cracking skin and routine use for AD and infantile 347 
seborrheic dermatitis. Published guidelines from a European roundtable meeting on best practice 348 
for infants recommend routine moisturizer/ moisturized cleanser use during and after bathing for 349 
infants who are at high risk of developing AD if its needed based on their skin condition.42 It is 350 
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unclear what influence the frequency and type of moisturizer used has on the development of 351 
AD.  Further studies are needed to inform best practices in the general population. 352 
 353 
Similar to moisturizer use, the type and frequency of bathing is an understudied area in newborn 354 
health.  Several studies found that exposure to water alone can be detrimental to the skin 355 
barrier,43 although no studies have evaluated the clinical effects of various methods of bathing or 356 
frequency on AD development. We found that more than half of the participants received 357 
baths/showers on 4 or more days per week. These results are in agreement with a previous  case-358 
control study that found the mean frequency of baths children received was 4-5 per week.37 The 359 
current AWHONN guidelines for neonates and infants recommended bathing infants every few 360 
days and no more than every other day.16 Additionally, AWHONN concluded that there were no 361 
clear benefits from daily bathing however they left the decision about frequency of bathing to be 362 
based on individual neonate’s needs considering the family beliefs and culture.16 Similar 363 
recommendations were published in 2009 by the European roundtable meeting on best practice 364 
for infants which recommend bathing 2-3 times a week using a mild cleanser and conclude that 365 
bathing does not harm the baby.42    366 
 367 
The strengths of our study include the use of primary care-based sampling to better understand 368 
AD burden in the primary care clinical setting, the use of clinics that are members of practice-369 
based research networks experienced in executing research protocols, and the inclusion of 370 
questions regarding skin care practices that are usually overlooked in AD surveys. Limitations of 371 
the study are that we cannot exclude the potential for selection bias that could yield artificially 372 
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inflated prevalence rates. Because of regional variation in AD prevalence, the prevalence data 373 
from the states included in this study may not be generalizable to all states in the U.S. In 374 
addition, the diagnosis of AD was made by parental report of a healthcare provider diagnosis 375 
rather than direct examination by a provider.  Last, possible failure to complete the survey 376 
existed for children with more complex healthcare visits such as those with chronic health 377 
conditions.  378 
 379 
In conclusion, our study found a large burden of AD in the primary care practice setting in the 380 
U.S. The majority of households use skincare practices that may be detrimental to the skin 381 
barrier of children not diagnosed with AD such as frequent bathing and the use of watery lotions 382 
frequently. Clinical trials will allow us to identify which skin care practices are optimal for 383 
reducing the significant burden of AD in the community.  384 
  385 
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